

8/13/05 10/693, 161

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:11:14 ON 13 AUG 2005

FILE 'REGISTRY' ENTERED AT 18:12:13 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added.   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
```

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=> Uploading C:\Program Files\Stnexp\Queries\10693161\10693161f.str
```



chain nodes :

11 12 13 14 15 16 17 18 19

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-16 4-11 11-12 12-13 13-14 13-15 16-17 17-18 17-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-2 1-6 1-16 2-3 3-4 4-5 4-11 5-6 5-7 6-10 7-8 8-9 9-10 11-12 12-13
13-14 13-15 16-17 17-18 17-19

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:CLASS 17:CLASS 18:CLASS
19:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 18:12:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 0 TO 0


L2 0 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 18:12:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 95 TO ITERATE

100.0% PROCESSED 95 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10693161\1069316gf.str



chain nodes :

1 2 9 10 11 12 13 14 15 16 17

ring nodes :

3 4 5 6 7 8

chain bonds :

1-14 1-4 2-9 2-3 9-10 10-11 11-12 11-13 14-15 15-16 15-17

ring bonds :

3-4 3-5 4-8 5-6 6-7 7-8

exact/norm bonds :

1-14 1-4 2-9 2-3 3-4 3-5 4-8 5-6 6-7 7-8 11-12 11-13 15-16 15-17

exact bonds :

9-10 10-11 14-15

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L4 STRUCTURE UPLOADED

=> d

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s L4
SAMPLE SEARCH INITIATED 18:14:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 24709 TO ITERATE

8.1% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 484777 TO 503583
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s L4 full
FULL SEARCH INITIATED 18:14:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 489333 TO ITERATE

100.0% PROCESSED 489333 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.08

L6 0 SEA SSS FUL L4

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 325.24 325.66

FILE 'REGISTRY' ENTERED AT 18:16:53 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161g.str



chain nodes :

1 2 9 10 11 12 13 14 15 16 17

ring nodes :

3 4 5 6 7 8

chain bonds :

1-14 2-9 9-10 10-11 11-12 11-13 14-15 15-16 15-17

ring bonds :

3-5 3-4 4-8 5-6 6-7 7-8

exact/norm bonds :

1-14 2-9 3-5 3-4 4-8 5-6 6-7 7-8 11-12 11-13 15-16 15-17

exact bonds :

9-10 10-11 14-15

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS

11:CLASS 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 24:CLASS

25:CLASS

L7 STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s L7
SAMPLE SEARCH INITIATED 18:17:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 19140 TO ITERATE

10.4% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 374519 TO 391081
PROJECTED ANSWERS: 6 TO 376

L8 1 SEA SSS SAM L7

=> s L7 full
FULL SEARCH INITIATED 18:17:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 384020 TO ITERATE

100.0% PROCESSED 384020 ITERATIONS 190 ANSWERS
SEARCH TIME: 00.00.08

L9 190 SEA SSS FUL L7

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.33 486.99

FILE 'CAPLUS' ENTERED AT 18:17:44 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L9
L10 2 L9



=> d ibib abs 1-2

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370892 CAPLUS
 DOCUMENT NUMBER: 140:374984
 TITLE: Preparation of [(diarylethyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
 INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl. 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1631	A	20021028		
	DK 2003-793	A	20030526	
	US 2002-423467P	P	20021104	
	WO 2003-DK722	W	20031027	

OTHER SOURCE(S): MARPAT 140:374984
 GI

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





AB Title compds. I (wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH₂)_n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkyne, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkyne, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR₈, such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:220310 CAPLUS
 DOCUMENT NUMBER: 140:270625
 TITLE: Preparation of [(bis(biphenyl)allyl)oxyl]phenoxy]acetic acids and analogs as PPAR₈ agonists for treatment of diabetes and related conditions
 INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl. 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UC, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499380	AA	20040318	CA 2003-2499380	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793608	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1301	A	20020905		
	DK 2003-784	A	20030523	
	US 2002-409814P	P	20020911	
	WO 2003-DK578	W	20030904	

OTHER SOURCE(S): MARPAT 140:270625
 GI

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title vinyl carboxylic acid derivs. I (wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH₂)_n; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkyne, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkyne, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator-activated receptor 8 (PPAR₈) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DBAL-H in THF (76%) followed by ADDP-catalyzed condensation with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR₈-mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).
 REFERENCES COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib abs 1-2 fhitstr

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370692 CAPLUS
 DOCUMENT NUMBER: 140:374984
 TITLE: Preparation of [(diarylallyl)sulfanyl]phenoxy)acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
 INVENTOR(S): Jeppeesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1631			A 20021028	
		DK 2003-793	A 20030526	
		US 2002-423467P	P 20021104	
		WO 2003-DK722	W 20031027	

OTHER SOURCE(S): MARPAT 140:374984
 GI


L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH₂)_n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, arylmethyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereopolymers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR₅, such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

IT 685138-70-9, (4-(3,3-Bis(4-bromophenyl)allyloxy)-2-methylphenoxy)acetic acid methyl ester
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (PPAR activator; preparation of ([(diarylallyl)sulfanyl]phenoxy)acets as PPAR activators for treatment of diabetes and related conditions)
 RN: 685138-70-9 CAPLUS
 CN: Acetic acid,
 (4-((3,3-bis(4-bromophenyl)-2-propenyl)oxy)-2-methylphenoxy)-, methyl ester (9CI) (CA INDEX NAME)

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220310 CAPLUS
 DOCUMENT NUMBER: 140:270625
 TITLE: Preparation of [(diarylallyl)sulfanyl]phenoxy)acetic acids and analogs as PPAR₅ agonists for treatment of diabetes and related conditions
 INVENTOR(S): Jeppeesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GM, ML, MR, NE, SN, TD, TG				
CA 2499380	AA	20040318	CA 2003-2499380	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793608	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1301			A 20020905	
		DK 2003-784	A 20030523	
		US 2002-409814P	P 20020911	
		WO 2003-DK578	W 20030904	

OTHER SOURCE(S): MARPAT 140:270625
 GI




AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently

O or S; Z = (CH₂)_n; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator-activated receptor 8 (PPAR8) agonists (no data). For example, 4,4'-dibromobiphenophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using K₂PdCl₄, Pd(Pt-Bu)₃J2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR8-mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

IT 673479-21-5, [4-(3,3-Bis(biphenyl-4-yl)allyloxy)-2-methylphenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses);
 (PPAR8 agonist; preparation of di(hetero)arylvinylic acids

as



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.98	503.97
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-2.92

STN INTERNATIONAL LOGOFF AT 18:20:17 ON 13 AUG 2005

10/693, 161a. 8/13/05

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE : 'HOME' ENTERED AT 16:56:55 ON 13 AUG 2005

=> fil req

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:57:03 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RX 860111-75-7

New CMS Information Use Policies – see the [HEALTH INFORMATION USE AGREEMENT](#) for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added,
* effective March 20, 2005. A new display format, IDERL, is now
* available and contains the CA role and document type information.
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10693161a.str



```

chain nodes :
1 2 3 4 5 7 8 9 11 12 15 16
chain bonds :
1-3 2-3 3-4 4-5 5-7 7-8 8-9 9-11 11-12 12-15 12-16
exact/norm bonds :
1-3 2-3 3-4 5-7 7-8 8-9 9-11 12-15 12-16
exact bonds :
4-5 11-12

```

G1:O,S

Match level :

1:Atom	2:Atom	3:CLASS	4:CLASS	5:CLASS	7:CLASS	8:Atom	9:CLASS	11:CLASS
12:CLASS	15:CLASS	16:CLASS						

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s L1

SAMPLE SEARCH INITIATED 16:57:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 212694 TO ITERATE

0.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L2 0 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 16:57:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 12.0% PROCESSED 509617 ITERATIONS 0 ANSWERS
< 17.7% PROCESSED 750811 ITERATIONS 537 ANSWERS
<-----User Break----->
< 21.8% PROCESSED 927924 ITERATIONS 537 ANSWERS
SEARCH ENDED BY USER
SEARCH TIME: 00.00.47

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 2313

L3 537 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.76 161.97

FILE 'CAPLUS' ENTERED AT 16:58:15 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8

FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L4 3 L3

=> d 1-3 ibib abs hitstr

TITLE: Preparation of [(diarylallyl)sulfanyl]phenoxylacetic acids and esters as PPAR activators for treatment of diabetes and related conditions
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXOZD
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
		W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, EG, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
		R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	DK 2002-1631	A 20021028
			DK 2003-793	A 20030526
			US 2002-423467P	P 20021104
			WO 2003-DK722	W 20031027

PRIORITY APPLN. INFO.: MARPAT 140:374984


OTHER SOURCE(S): GI

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methyl ester 685139-12-2P, [4-[(3,3-Bis(4-bromophenyl)-2-ethoxyallyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685139-17-7P, (2)-[4-[(3-(Benzob)thiophen-2-yl)-3-(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-21-3P, (2)-[4-[(3-(4-Bromophenyl)-3-(5-methylthiophen-2-yl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685139-24-6P, [4-[(3-(furan-2-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685139-32-6P, (2)-(4-[(3-(5-Methylthiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy)acetic acid 685139-35-9P, [4-[(3-(Benzob)thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-38-2P, [4-[(3-(Benzob)thiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid 685139-77-6P, (2)-[4-[(3-(3-(furan-2-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl)-2-methylphenoxy]acetic acid 685139-95-8P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685139-97-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid 685139-99-2P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-chlorophenoxy]acetic acid as PPAR activators; prep. of [(diarylallyl)sulfanyl]phenoxylacetic acids as PPAR activators; prep. of [(diarylallyl)sulfanyl]phenoxylacetates as PPAR activators for treatment of diabetes and related conditions)



RN 673479-08-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 685138-63-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-iodophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-66-3 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-fluorophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = -(un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n, n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)alkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, aralkyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR δ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobiphenone with tri-Et phosphonate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).


IT 673479-08-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-63-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-66-3P, [4-[(3,3-Bis(4-fluorophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-70-9P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-72-1P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-77-6P, [4-[(3,3-Bis(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 685138-84-5P, [4-[(3,3-Bis(4-fluorophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-91-4P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-95-8P, [4-[(3,3-Bis(4-trifluoromethylphenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-97-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid methyl ester 685138-99-2P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-chlorophenoxy]acetic acid




RN 685138-70-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)oxy]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-72-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-77-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-trifluoromethylphenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-84-5 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-fluorophenyl)-2-propenyl)thio]-2-ethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 685138-91-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenylthio)-2-ethylphenoxy]-methyl ester (9CI) (CA INDEX NAME)




RN 685138-95-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3-(trifluoromethyl)phenyl]-2-propenylthio)-2-ethylphenoxy]-methyl ester (9CI) (CA INDEX NAME)




RN 685138-97-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenylthio)-2-ethylphenoxy]-methyl ester (9CI) (CA INDEX NAME)



RN 685138-99-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenylthio)-2-chlorophenoxy]-methyl ester (9CI) (CA INDEX NAME)




RN 685139-12-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-ethoxy-2-propenylthio)-2-methylphenoxy]-methyl ester (9CI) (CA INDEX NAME)




RN 685139-17-7 CAPLUS
CN Acetic acid, [4-[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-21-3 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-[4-(methylthio)phenyl]-2-propenylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-24-6 CAPLUS
CN Acetic acid, [4-[(3-(2-furanyl)-3-{4-(trifluoromethyl)phenyl}-2-propenylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-32-6 CAPLUS
CN Acetic acid, [2-methyl-4-[(2Z)-3-[4-(methylthio)phenyl]-3-[4-(trifluoromethyl)phenyl]-2-propenylthio]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 685139-35-9 CAPLUS
CN Acetic acid, [4-[(3-benzo[b]thien-3-yl-3-(4-(trifluoromethyl)phenyl)-2-propenylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-38-2 CAPLUS
CN Acetic acid, [4-[(3-benzo[b]thien-2-yl-3-[4-(trifluoromethyl)phenyl]-2-propenylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




IT 673479-09-9P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685138-57-2P, [4-[(3,3-Bis(4-bromophenyl)allyl)-2,6-diphenylphenoxy]acetic acid ethyl ester 685138-61-6P 685138-64-1P, [4-[(3,3-Bis(4-iodophenyl)allyl)-2-methylphenoxy]acetic acid 685138-69-6P, [4-[(3,3-Bis(4-fluorophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685138-71-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685138-75-4P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 685138-80-3P, [4-[(3,3-Bis(4-fluorophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid 685138-93-6P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid 685138-96-9P, [4-[(3,3-Bis(3-trifluoromethylphenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid 685138-98-1P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-ethylphenoxy]acetic acid 685138-10-0P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-chlorophenoxy]acetic acid 685139-15-5P, [4-[(3,3-Bis(4-bromophenyl)-2-ethoxyallyl)sulfanyl]-2-methylphenoxy]acetic acid 685139-20-2P 685139-23-5P 685139-31-5P 685139-34-8P 685139-37-1P 685139-40-6P 685139-41-7P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-chlorophenoxy]acetic acid 685139-43-9P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-chlorophenoxy]acetic acid 685139-46-2P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-trifluoromethylphenoxy]acetic acid 685139-48-4P,

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [4-[(3-methylchlorophenyl)allyl]sulfanyl]-2-trifluoromethylphenoxy)acetic acid 685139-51-9P,
 [4-[(3,3-Di(furan-2-yl)allyl)sulfanyl]-2-trifluoromethylphenoxy)acetic acid 685139-53-1P, [4-[(3,3-Bis(4-iodophenyl)allyl)sulfanyl]-2-methoxyphenoxy)acetic acid 685139-56-4P, [4-[(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-methoxyphenoxy)acetic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (PPAR activator; prepn. of [(diaryllallyl)sulfanyl]phenoxy)acetates as PPAR activators for treatment of diabetes and related conditions)
 RN 673479-09-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 685138-57-2 CAPLUS
 CN Acetic acid, [[5'-(3,3-bis(4-bromophenyl)-2-propenyl)oxy]-1,1':3',1'''-terphenyl]-2'-yl]oxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 685138-61-8 CAPLUS
 CN L-Arginine, mono[[5'-(3,3-bis(4-bromophenyl)-2-propenyl)oxy]-1,1':3',1'''-terphenyl]-2'-yl]oxy]acetate (9CI) (CA INDEX NAME)

CM 1

CRN 685138-60-7
 CMF C35 H26 Br2 O4


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




CH 2

CRN 74-79-3
 CMF C6 H14 N4 O2


Absolute stereochemistry.




RN 685138-64-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-iodophenyl)-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-69-6 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-fluorophenyl)-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 685138-71-0 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-75-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 685138-82-3 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[3-(trifluoromethyl)phenyl]-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-90-3 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-fluorophenyl)-2-propenyl)thio]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-93-6 CAPLUS


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-96-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[3-(trifluoromethyl)phenyl]-2-propenyl)thio]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)




RN 685138-98-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 685138-10-0 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 685138-15-5 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-ethoxy-2-propenyl)thio]-2-




RN 685139-20-2 CAPLUS
CN L-Lysine, mono[14-[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-17-7
CMF C26 H21 Br O3 S2


Double bond geometry as shown.



CM 2


CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-23-5 CAPLUS
CN L-Lysine, mono[14-[(2Z)-3-(4-bromophenyl)-3-(4-(methylthio)phenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)


CM 1

CRN 685139-21-3
CMF C25 H23 Br O3 S2

CM 2


CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-31-5 CAPLUS
CN L-Lysine, mono[14-[(3-(2-furanyl)-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)


CM 1

CRN 685139-24-6
CMF C23 H19 F3 O4 S

CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 685139-34-8 CAPLUS
CN L-Lysine, mono[2-methyl-4-[(2Z)-3-[4-(methylthio)phenyl]-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-32-6
CMF C26 H23 F3 O3 S2


Double bond geometry as shown.



CM 2


CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-37-1 CAPLUS
CN L-Lysine, mono[14-[(3-benzo[b]thien-3-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)


CM 1

CRN 685139-35-9
CMF C27 H21 F3 O3 S2

CM 2


CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-40-6 CAPLUS
CN L-Lysine, mono[14-[(3-benzo[b]thien-2-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)


CM 1

CRN 685139-38-2
CMF C27 H21 F3 O3 S2


CM 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.




RN 685139-41-7 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 685139-43-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 685139-46-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 685139-48-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3-methyl-2-thienyl)-2-propenyl)thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT 685139-19-9P, Ethyl (2-[(3-(Benz[b]thiophen-2-yl)-3-(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-22-4P, Ethyl (2-[(3-(4-Bromophenyl)-3-(5-methylthiophen-2-yl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-30-4P, Ethyl (2-[(3-(4-Furan-2-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-33-7P, Ethyl (2-[(3-(5-Methylthiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-36-0P, Ethyl (2-[(3-(benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-39-3P, Ethyl (2-[(3-(benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl)sulfanyl]-2-methylphenoxy)acetate 685139-42-9P, [4-(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-chlorophenoxy)acetic acid ethyl ester 685139-45-1P, [4-(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-chlorophenoxy)acetic acid ethyl ester 685139-47-3P, [4-(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-trifluoromethylphenoxy)acetic acid ethyl ester 685139-50-8P, [4-(3,3-Bis(3-methylthiophen-2-yl)allyl)sulfanyl]-2-trifluoromethylphenoxy)acetic acid ethyl ester 685139-52-0P, [4-(3,3-Bis(2-furanyl)allyl)sulfanyl]-2-trifluoromethylphenoxy)acetic acid ethyl ester 685139-55-3P, [4-(3,3-Bis(4-iodophenyl)allyl)-2-methoxyphenoxy]acetic acid methyl ester 685139-57-5P, [4-(3,3-Bis(4-chlorophenyl)allyl)sulfanyl]-2-methoxyphenoxy)acetic acid methyl ester R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; preparation of [(diarylallyl)sulfanyl]phenoxy)acetates as PPAR activators for treatment of diabetes and related conditions)

RN 685139-19-9 CAPLUS
CN Acetic acid, [4-[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 685139-22-4 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-[4-(methylthio)phenyl]-2-propenyl]thio]-2-methylphenoxy-, ethyl ester (9CI) (CA INDEX NAME)




RN 685139-51-9 CAPLUS
CN Acetic acid, [4-[(3,3-di-2-furanyl-2-propenyl)thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 685139-53-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-iodophenyl)-2-propenyl)thio]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-56-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-chlorophenyl)-2-propenyl)thio]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)




RN 685139-30-4 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(2-furanyl)-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-33-7 CAPLUS
CN Acetic acid, [2-methyl-4-[(2Z)-3-[4-(methylthio)phenyl]-2-propenyl]thio]-2-methylphenoxy-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 685139-36-0 CAPLUS
CN Acetic acid, [4-[(2Z)-3-benzo[b]thien-3-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy-, ethyl ester (9CI) (CA INDEX NAME)


686774-34-5P 686774-35-6P 686774-36-7P
 686774-37-6P 686774-38-9P 686774-39-0P
 686774-40-3P 686774-41-4P 686774-42-5P
 686774-43-6P 686774-44-7P 686774-45-8P
 686774-46-9P 686774-47-0P 686774-48-1P
 686774-49-2P 686774-50-5P 686774-51-6P
 686774-52-7P 686774-53-8P 686774-54-9P
 686774-55-0P 686774-56-1P 686774-59-4P
 686774-60-7P 686774-61-8P 686774-62-9P
 686774-63-0P 686774-64-1P 686774-66-3P
 686774-67-4P 686774-68-5P 686774-69-6P
 686774-70-9P 686774-71-0P 686774-72-1P
 686774-73-2P 686774-75-4P 686774-76-5P
 686774-78-7P 686774-79-8P 686774-82-3P
 686774-84-5P 686774-86-7P 686774-88-9P
 686774-90-3P 686774-92-5P 686774-93-6P
 686774-95-8P 686774-96-9P 686774-97-0P
 686774-98-1P 686774-99-2P 686775-01-0P
 686775-03-1P 686775-03-3P 686775-06-4P
 686775-07-5P 686775-08-6P 686775-09-7P
 686775-10-0P 686775-11-1P 686775-12-2P
 686775-13-3P 686775-15-5P 686775-17-7P
 686775-19-9P 686775-21-3P 686775-23-5P
 686775-24-6P 686775-25-7P 686775-27-9P
 686775-29-1P 686775-30-4P 686775-31-5P
 686775-33-7P 686775-34-8P 686775-36-0P
 686775-38-2P 686775-40-6P 686775-43-9P
 686775-44-0P 686775-45-1P 686775-46-2P
 686775-47-3P 686775-48-4P 686775-49-5P
 686775-50-8P 686775-51-9P 686775-52-0P
 686775-53-1P 686775-54-2P 686775-59-7P
 686775-62-2P 686775-64-4P 686775-66-6P
 686775-68-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of biphenylallylsulfanylphenoxycacetates and related compds. for treating peroxisome proliferator activated receptor (PPAR) mediated diseases)


RN 686774-25-4 CAPLUS
 CN Acetic acid, [4-[(3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-26-5 CAPLUS
 CN Acetic acid, [4-[(3-(4-bromophenyl)-3-[3'-(trifluoromethyl)(1,1'-biphenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-27-6 CAPLUS
 CN Acetic acid, [4-[(3-(4-bromophenyl)-3-[1,1':4',1''-terphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-28-7 CAPLUS
 CN Acetic acid, [2-methyl-4-[(3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy] - (9CI) (CA INDEX NAME)




RN 686774-29-8 CAPLUS
 CN Acetic acid, [4-[(3-[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-30-1 CAPLUS
 CN Acetic acid, [4-[(3-benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)



RN 686774-31-2 CAPLUS
 CN Acetic acid, [4-[(3-benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-32-3 CAPLUS
 CN Acetic acid, [4-[(3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 686774-33-4 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-fluorophenyl)-2-propenyl]thio]phenoxy] - (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-34-5 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-fluorophenyl)-2-propenyl]thio]phenoxy] - (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-35-6 CAPLUS


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-chlorophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-36-7 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-chlorophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-37-8 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-bromophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 686774-38-9 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-bromophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-39-0 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-iodophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-40-3 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-iodophenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-41-4 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-methoxyphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 686774-42-5 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-methoxyphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-43-6 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-44-7 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-(trifluoromethoxy)phenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-45-8 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-methylphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-46-9 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-methylphenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-47-0 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(2-(trifluoromethyl)phenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-48-1 CAPLUS


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-[2-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-49-2 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-fluorophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-50-5 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-fluorophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-51-6 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-chlorophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-52-7 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-chlorophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 686774-53-8 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-54-9 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-bromophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-55-0 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-iodophenyl)-2-propenyl]thio]phenoxy)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-56-1 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-iodophenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-59-4 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-methoxyphenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-60-7 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-methoxyphenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-61-8 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-(trifluoromethoxy)phenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 686774-62-9 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-(trifluoromethoxy)phenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-63-0 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(3-methylphenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-64-1 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-methylphenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-66-3 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-(trifluoromethyl)phenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-67-4 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(3-(trifluoromethyl)phenyl)-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 686774-68-5 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-69-6 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-fluorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-70-9 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 686774-73-2 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686774-75-4 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-76-5 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-71-0 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-chlorophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686774-72-1 CAPLUS
 CN Acetic acid, [4-[(3-[1,1'-biphenyl]-4-yl-3-(4-bromophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 686774-78-7 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-iodophenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-79-8 CAPLUS
 CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-methoxyphenyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-82-3 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-methoxyphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-84-5 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-[4-(trifluoromethoxy)phenyl]-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-86-7 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-[4-(trifluoromethoxy)phenyl]-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-88-9 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-(4-methylphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-90-3 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(4-methylphenyl)-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-92-5 CAPLUS
CN Acetic acid, [4-[(2E)-3-[1,1'-biphenyl]-4-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-93-6 CAPLUS
CN Acetic acid, [4-[(2Z)-3-[1,1'-biphenyl]-4-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-95-8 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-fluorophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]phenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-96-9 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-97-0 CAPLUS
 CN Acetic acid, [4-[(3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686774-98-1 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686774-99-2 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-01-9 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-fluorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-03-1 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-05-3 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-06-4 CAPLUS
 CN Acetic acid, [4-[(2Z)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-07-5 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4'-chlorobiphenyl)-4-yl]-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-08-6 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4'-chlorobiphenyl)-4-yl]-3-(4-fluorophenyl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-09-7 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-fluorophenyl)-3-(3'-methoxybiphenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-10-0 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-(3'-methoxybiphenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-11-1 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-fluorophenyl)-3-(4'-methoxybiphenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-12-2 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-fluorophenyl)-3-(4'-methoxybiphenyl)-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-13-3 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-chlorophenyl)-3-[2'-(trifluoromethyl)biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-15-5 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-chlorophenyl)-3-[2'-(trifluoromethyl)biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-17-7 CAPLUS
CN Acetic acid, [4-[(3-(4-chlorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 686775-19-9 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-chlorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-21-3 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-chlorophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-23-5 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4-chlorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-24-6 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-chlorophenyl)-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-25-7 CAPLUS
CN Acetic acid, [4-[(2E)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-27-9 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686775-29-1 CAPLUS
CN Acetic acid, [4-[(2E)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-30-4 CAPLUS

CN Acetic acid, [4-[(2Z)-3-(4'-chlorobiphenyl)-4-yl]-3-(4-chlorophenyl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-31-5 CAPLUS

CN Acetic acid, [4-[(2E)-3-(4-chlorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-33-7 CAPLUS

CN Acetic acid, [4-[(2Z)-3-(4-chlorophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-34-8 CAPLUS

CN Acetic acid, [4-[(2E)-3-(4-chlorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-36-0 CAPLUS

CN Acetic acid, [4-[(2Z)-3-(4-chlorophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-38-2 CAPLUS

CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-40-6 CAPLUS

CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-43-9 CAPLUS


CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-44-0 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-45-1 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-46-2 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-47-3 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-48-4 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-49-5 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-50-8 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-51-9 CAPLUS
 CN Acetic acid, [4-[(2E)-3-(4-bromophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-52-0 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-53-1 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686775-54-2 CAPLUS
CN Acetic acid, [4-[(2Z)-3-(4-bromophenyl)-3-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 686775-59-7 CAPLUS
CN L-lysine, mono[[2-methyl-4-[(3-[5-(5-methyl-2-thienyl)-2-propenyl]phenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1

CRN 686774-28-7
CMF C29 H24 O4 S3



CH 2


CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.

RN 686775-62-2 CAPLUS
CN L-lysine, mono[[4-[(3-[1,1'-biphenyl]-4-yl)-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1


CRN 686774-29-8
CMF C28 H24 O4 S



CH 2

CRN 56-87-1


Absolute stereochemistry.



RN 686775-64-4 CAPLUS
CN L-lysine, mono[[4-[(3-benzo[b]thien-3-yl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1


CRN 686774-30-1
CMF C32 H26 O3 S2



CH 2

CRN 56-87-1
CMF C6 H14 N2 O2


Absolute stereochemistry.



RN 686775-66-6 CAPLUS
CN L-lysine, mono[[4-[(3-benzo[b]thien-2-yl)-3-[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CH 1


CRN 686774-31-2
CMF C32 H26 O3 S2



CM 2

CRN 56-87-1
CNF C6 H14 N2 O2


Absolute stereochemistry.



RN 686775-68-8 CAPLUS

CN L-Lysine, mono[4-[(3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]acetate (9CI) (CA INDEX NAME)


CM 1

CRN 686774-32-3
CNF C29 H26 O3 S2

CM 2

CRN 56-87-1
CNF C6 H14 N2 O2

Absolute stereochemistry.



IT 673479-09-BP 673479-09-9P 686775-57-5P


686775-59-5P 686775-61-1P 686775-63-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenylallylsulfanylphenoxycarbonates and related compds.)

for treating peroxisome proliferator activated receptor (PPAR) mediated diseases)


RN 673479-09-8 CAPLUS

CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 673479-09-9 CAPLUS

CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]-, (9CI) (CA INDEX NAME)




RN 686775-57-5 CAPLUS

CN Acetic acid, [4-[(3-(5-bromo-2-benzofuranyl)-3-(2-thienyl)-2-propenyl)thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-58-6 CAPLUS


CN Acetic acid, [2-methyl-4-[(3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl)thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-61-1 CAPLUS


CN Acetic acid, [4-[(22)-3-[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 686775-63-3 CAPLUS

CN Acetic acid, [4-[(3-benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-65-5 CAPLUS


CN Acetic acid, [4-[(3-benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-67-7 CAPLUS

CN Acetic acid, [4-[(22)-3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.





ACCESSION NUMBER: 2004220310 CAPLUS

DOCUMENT NUMBER: 140:270625

TITLE: Preparation of [[{bis(biphenylyl)allyl}oxy]phenoxy]acetic acids and analogs as PPAR δ agonists for treatment of diabetes and related conditions
 INVENTOR(S): Jeppesen, Lone; Møgensen, John Patrick; Petersson, Ingrid; Sauerberg, Per
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 78 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SB, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499380	AA	20040318	CA 2003-2499380	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793601	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1301	A	20020905		
	DK 2003-784	A	20030523	
	US 2002-409814P	P	20020911	
	WO 2003-DK578	W	20030904	
OTHER SOURCE(S): MARPAT 140:270625				
GI				




AB Title vinyl carboxylic acid derivs. I [wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)acylene; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH₂)_n; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arythio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, or aryl or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymers thereof] were prepared as peroxisome proliferator-activated receptor δ (PPAR δ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Bt phosphonacetate in the presence of NaH in toluene to give Et 3,3'-bis(4-(bromophenoxy)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by AADP-catalyzed condensation with (4-mercaptop-2-methoxy)acetic acid Me ester in THF (88%) afforded [4-(3,3'-bis(4-(bromophenoxy)allylsulfanyl)-2-methoxyphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using

KF, Pd²⁺(dba)₃, and Pd[P(t-Bu)₃]2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR δ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).


IT 673479-07-7P, [4-[(3,3'-bis(biphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-10-2P, [4-[(3,3'-bis(4'-methylphenyl)biphenyl-4-yl)allyl]sulfanyl]-2-methoxyphenoxy]acetic acid 673479-11-3P, [4-[(3,3'-bis(3'-trifluoromethylbiphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-12-4P, 673479-13-5P, [4-[(3,3'-bis(3'-dimethylcarbamoyl)biphenyl-4-yl)allyl]sulfanyl]-2-methoxyphenoxy]acetic acid 673479-14-6P, [4-[(3,3'-bis(4-(pyridin-3-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-15-7P, [4-[(3,3'-bis(4-(pyridin-3-yl)phenyl)allyl)sulfanyl]-2-trifluoromethylphenoxy]acetic acid 673479-21-5P, methylphenoxy]acetic acid 673479-22-6P, [4-[(3,3'-bis(4-

methylfuran-2-yl)phenyl)allyl]oxy]-2-methoxyphenoxy]acetic acid 673479-23-7P, [4-[(3,3'-bis(4-(furan-2-yl)phenyl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-24-8P, [4-[(3,3'-bis(4-(5-methylfuran-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-25-9P, [4-[(3,3'-bis(4-(furan-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-26-0P, [4-[(3,3'-bis(4-(5-chlorothiophen-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-27-1P, [4-[(3,3'-bis(4-(5-chlorothiophen-2-yl)phenyl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-28-2P, [4-[(3,3'-bis(4-(thiophen-2-yl)phenyl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-29-3P, [4-[(3,3'-bis(4-(thiophen-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-30-6P, [4-[(3,3'-bis(4-(5-acetylthiophen-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-31-7P, [4-[(3,3'-bis(4-(5-acetylthiophen-2-yl)phenyl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-32-8P, [4-[(3,3'-bis(4-(5-acetylthiophen-2-yl)phenyl)oxy)-2-methoxyphenoxy]acetic acid 673479-33-9P, [4-[(3,3'-bis(4-(5-acetylthiophen-2-yl)phenyl)oxy)-2-methoxyphenoxy]acetic acid 673479-34-0P, [4-[(3,3'-bis(3-(dimethylcarbamoyl)biphenyl-4-yl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-35-1P, [4-[(3,3'-bis(3'-methylsulfonylbiphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-36-2P, [4-[(3,3'-bis(3'-methylsulfonylbiphenyl-4-yl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-37-3P, [4-[(3,3'-bis(3'-aminobiphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-38-4P, [4-[(3,3'-bis(3'-aminobiphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-39-5P, [4-[(3,3'-bis(3-(dimethylcarbamoyl)biphenyl-4-yl)allyl)oxy]-2-methoxyphenoxy]acetic acid 673479-40-6P, [4-[(3,3'-bis(4-(aminobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-41-7P, [4-[(3,3'-bis(4-(aminobiphenyl-4-yl)allyl)oxy)-2-methoxyphenoxy]acetic acid 673479-42-8P, [4-[(3,3'-bis(4-(pyridin-2-yl)phenyl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-43-1P, [4-[(3,3'-bis(4-(methanesulfonyl)biphenyl-4-yl)allyl)sulfanyl]-2-methoxyphenoxy]acetic acid 673479-44-2P, [4-[(3,3'-bis(4-(methoxybiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-45-3P, [4-[(3,3'-bis(4-(methoxybiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-46-4P, [4-[(3,3'-bis(4-(3-aminobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-47-5P, [4-[(3,3'-bis(4-(3-aminobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-48-6P, [4-[(3,3'-bis(4-(3-aminobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-49-7P, [4-[(3,3'-bis(4-(3-aminobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-50-8P, [4-[(3,3'-bis(4-(trifluoromethylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-51-9P, [4-[(3,3'-bis(4-(trifluoromethylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-52-0P, [4-[(3,3'-bis(4-(trifluoromethylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-53-1P, [4-[(3,3'-bis(4-(chlorobiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-54-2P, [4-[(3,3'-bis(4-(tert-butylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-55-3P, [4-[(3,3'-bis(4-(acetyl)biphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-56-4P, [4-[(3,3'-bis(4-(acetyl)biphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-57-5P, [4-[(3,3'-bis(4-(phenoxybiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-58-6P, [4-[(3,3'-bis(4-(phenoxybiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-59-7P, [4-[(3,3'-bis(4-isopropylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-60-8P, [4-[(3,3'-bis(4-isopropylbiphenyl-4-yl)allyl)sulfanyl)-2-methoxyphenoxy]acetic acid 673479-61-9P]


- L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
- RN 673481-76-0P, [4-[(3,3-Bis(4'-acetyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-79-3P, [4-[(3,3-Bis(4'-phenoxyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-80-6P, [4-[(3,3-Bis(4'-phenoxyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-82-6P, [4-[(3,3-Bis(4'-isopropyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-84-0P, [4-[(3,3-Bis(4'-isopropyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-87-3P, [4-[(3,3-Bis(3',4'-difluorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-90-6P, [4-[(3,3-Bis(3',4'-difluorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673481-93-1P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673481-94-2P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-97-5P, [4-[(3,3-Bis(3'-chloro-4'-fluorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673481-98-6P, [4-[(3,3-Bis(3'-chloro-4'-fluorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-00-3P, [4-[(3,3-Bis(3'-chloro-4'-fluorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylfuran-2-ylphenyl]oxy]-2-methylphenoxy]acetic acid 673482-02-5P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethylallyl)oxy]-2-methylphenoxy]acetic acid 673482-05-8P, [4-[(3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethylallyl)sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-07-0P, [4-[(3,3-Bis(4-(4-chlorothiophen-2-yl)phenyl)-2-ethylallyl)sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-11-6P, [4-[(3,3-Bis(4-(pyridin-3-yl)phenyl)-2-ethylallyl)oxy]-2-methylphenoxy]acetic acid 673482-13-0P, [4-[(3,3-Bis(4-(pyridin-3-yl)phenyl)-2-ethylallyl)sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-14-9P, [4-[(3,3-Bis(3'-methoxybiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-16-1P, [4-[(3,3-Bis(3'-methoxybiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-19-4P, [4-[(3,3-Bis(3'-trifluoromethoxybiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-21-8P, [4-[(3,3-Bis(3'-trifluoromethoxybiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-22-9P, [4-[(3,3-Bis(3'-methylbiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-24-1P, [4-[(3,3-Bis(3'-methylbiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-27-4P, [4-[(3,3-Bis(3'-trifluoromethylbiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-29-6P, [4-[(3,3-Bis(3'-trifluoromethylbiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-31-0P, [4-[(3,3-Bis(3'-chlorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-34-3P, [4-[(3,3-Bis(3'-chlorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-36-5P, [4-[(3,3-Bis(3'-tert-butylbiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-39-6P, [4-[(3,3-Bis(3'-acetyl biphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-42-3P, [4-[(3,3-Bis(3'-acetyl biphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-45-6P, [4-[(3,3-Bis(3'-phenoxybiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methylphenoxy]acetic acid 673482-46-9P, [4-[(3,3-Bis(3'-phenoxybiphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid 673482-51-4P, [4-[(3,3-Bis(3'-isopropyl biphenyl)-4-yl)-2-ethylallyl]sulfanyl]oxy]-2-methylphenoxy]acetic acid
- RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
- (PPAR δ agonist; prepn. of di(hetero)arylvinylic carboxylic acids as PPAR δ agonists; prepn. of di(hetero)arylvinylic carboxylic acids as PPAR δ agonists)
- L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
- RN 673479-13-5 CAPLUS, Acetic acid, [4-[(3,3-bis[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy] (9CI) (CA INDEX NAME)
-
- RN 673479-14-6 CAPLUS, Acetic acid, [4-[(3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]thio]-2-methylphenoxy] (9CI) (CA INDEX NAME)
-
- RN 673479-15-7 CAPLUS, Acetic acid, [4-[(3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]thio)-2-(trifluoromethyl)phenoxy] (9CI) (CA INDEX NAME)
-
- RN 673479-21-5 CAPLUS, Acetic acid, [4-[(3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy] (9CI) (CA INDEX NAME)
-
- RN 673479-22-6 CAPLUS, Acetic acid, [4-[(3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl)oxy]-2-methylphenoxy] (9CI) (CA INDEX NAME)
-




RN 673479-23-7 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]oxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-24-8 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]thio}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-25-9 CAPLUS




RN 673479-26-0 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]thio}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-27-1 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl]oxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-28-2 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]oxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-29-3 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(2-thienyl)phenyl]-2-propenyl]thio}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-30-6 CAPLUS




RN 673479-31-7 CAPLUS
 CN Acetic acid, [4-[{[3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl]oxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)





RN 673479-32-8 CAPLUS
 CN Acetic acid, [4-[{bis[4-(5-acetyl-2-thienyl)phenyl]methylene}butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-33-9 CAPLUS
CN Acetic acid, [4-[{2-(bis[4-(5-acetyl-2-thienyl)phenyl]methylene)butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-34-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-y1}-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-36-2 CAPLUS
CN Acetic acid, [4-[{3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-y1]-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-37-3 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3'-amino[1,1'-biphenyl]-4-y1)-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-38-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3'-amino[1,1'-biphenyl]-4-y1)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-39-5 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-amino[1,1'-biphenyl]-4-y1)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-40-8 CAPLUS




RN 673479-41-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-42-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-43-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-44-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(methoxysulfonyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-45-3 CAPLUS




RN 673479-46-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-47-5 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-48-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-49-7 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-50-0 CAPLUS




RN 673479-51-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-52-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-(chloro)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-53-3 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-chlorobiphenyl)-4-yl}-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-54-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-(1,1-dimethylethyl)-1,1'-biphenyl)-4-yl}-2-propenyl]oxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-55-5 CAPLUS




RN 673479-56-6 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-acetyl-1,1-dimethylethyl)-1,1'-biphenyl}-4-yl}-2-propenyl]oxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-57-7 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-phenoxy-1,1'-biphenyl)-4-yl}-2-propenyl]oxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-58-8 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-phenoxy-1,1'-biphenyl)-4-yl}-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-59-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis(4'-(1-methylethyl)-1,1'-biphenyl)-4-yl}-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-60-2 CAPLUS




RN 673479-61-3 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',4'-difluoro-1,1'-biphenyl)-4-yl}-2-propenyl]oxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-62-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',4'-difluoro-1,1'-biphenyl)-4-yl}-2-propenyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673479-63-5 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-64-6 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-65-7 CAPLUS




RN 673479-66-8 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-67-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-68-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-69-1 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-70-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-71-5 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-72-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-73-7 CAPLUS
CN Acetic acid, [4-[(2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylene]butoxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-74-8 CAPLUS
CN Acetic acid, [4-[(2-[bis[4-(4-acetyl-2-thienyl)phenyl]methylenethio]butyl)thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-75-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-76-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-(dimethylamino)carbonyl)[1,1'-biphenyl]-4-yloxy)-2-propenyl]thio]phenoxo- (9CI) (CA INDEX NAME)




RN 673479-77-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-methoxy[1,1'-biphenyl]-4-yloxy)-2-propenyl]thio)phenoxo- (9CI) (CA INDEX NAME)




RN 673479-78-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-methoxy[1,1'-biphenyl]-4-yloxy)-2-propenyl]thio)phenoxo- (9CI) (CA INDEX NAME)



RN 673479-79-3 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yloxy)-2-propenyl]thio)phenoxo- (9CI) (CA INDEX NAME)




RN 673479-80-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yloxy)-2-propenyl]thio)phenoxo- (9CI) (CA INDEX NAME)




RN 673479-81-7 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-82-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-83-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-87-3 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-88-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-84-0 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-85-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl)thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-86-2 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-89-5 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-90-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl)thio]-2-methylphenoxy]-(9CI) (CA INDEX NAME)




RN 673479-91-9 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis[3'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-92-0 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[3'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-93-1 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-94-2 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-95-3 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-96-4 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-97-5 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673479-98-6 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673479-99-7 CAPLUS
 CN Acetic acid, [4-[{3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl}thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-00-7 CAPLUS
 CN Acetic acid, [4-[{3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl}oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-01-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl}oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-02-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(2-furanyl)phenyl]-2-propenyl}oxy]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-03-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl}thio]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-04-1 CAPLUS




RN 673480-05-2 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl}thio]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-06-3 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl}oxy]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-07-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(2-thienyl)phenyl]-2-propenyl}oxy]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-10-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl}oxy]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-11-0 CAPLUS
CN Acetic acid, [4-[2-[bis[4-(5-acetyl-2-thienyl)phenyl]methylene]butoxy]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-08-5 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(2-thienyl)phenyl]-2-propenyl}thio]phenoxy]-
(9CI) (CA INDEX NAME)




RN 673480-09-6 CAPLUS




RN 673480-12-1 CAPLUS
CN Acetic acid, [4-[(2-[bis(4-(5-acetyl-2-thienyl)phenyl)methylene]butyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-13-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-14-3 CAPLUS




RN 673480-15-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3'-(amino)[1,1'-biphenyl]-4-yl]-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-16-5 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3'-(amino)[1,1'-biphenyl]-4-yl]-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-17-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4'-amino[1,1'-biphenyl]-4-yl]-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-18-7 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4'-amino[1,1'-biphenyl]-4-yl]-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-19-8 CAPLUS




RN 673480-20-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-21-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-22-3 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-23-4 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-24-5 CAPLUS




RN 673480-25-6 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl)thio)phenoxy]- (9CI) (CA INDEX NAME)




RN' 673480-26-7 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-28-9 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy)- (9CI) (CA INDEX NAME)




RN 673480-30-3 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio)phenoxy)- (9CI) (CA INDEX NAME)




RN 673480-32-5 CAPLUS




RN 673480-33-6 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-34-7 CAPLUS
CN Acetic acid, [4-((3,3-bis(4'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl)oxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-35-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-chlorobiphenyl)-4-yl)-2-propenyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-36-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4'-(1,1-dimethylethyl)(1,1'-biphenyl)-4-yl]-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-37-0 CAPLUS




RN 673480-38-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-39-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-40-5 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-41-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-42-7 CAPLUS




RN 673480-43-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4'-[1-methylethyl][1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-44-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3',4'-difluorobiphenyl)-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-45-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',4'-difluorobiphenyl)-4-yl}-2-propenyl]oxy]phenoxymethyl ester (CA INDEX NAME)




RN 673480-46-1 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3',5'-dichlorobiphenyl)-4-yl}-2-propenyl]thio]phenoxymethyl ester (CA INDEX NAME)




RN 673480-47-2 CAPLUS




RN 673480-48-3 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3'-chloro-4'-fluorobiphenyl)-4-yl}-2-propenyl]oxy]phenoxymethyl ester (CA INDEX NAME)




RN 673480-49-4 CAPLUS
CN Acetic acid, [4-[{3,3-bis(3'-chloro-4'-fluorobiphenyl)-4-yl}-2-propenyl]thio]phenoxymethyl ester (CA INDEX NAME)




RN 673480-50-7 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-methyl-2-furyl)phenyl]-2-propenyl}oxy]phenoxymethyl ester (CA INDEX NAME)




RN 673480-51-8 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-methyl-2-furyl)phenyl]-2-propenyl}thio]phenoxymethyl ester (CA INDEX NAME)




RN 673480-52-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-propenyl}thio]phenoxymethyl ester (CA INDEX NAME)




RN 673480-53-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-propenyl}oxy]phenoxymethyl ester (CA INDEX NAME)




RN 673480-54-1 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl}thio]phenoxymethyl ester (CA INDEX NAME)




RN 673480-55-2 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-propenyl}oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-56-3 CAPLUS
CN Acetic acid, [4-[2-{bis[4-(4-acetyl-2-thienyl)phenyl]methylene}butoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-57-4 CAPLUS
CN Acetic acid, [4-[[2-{bis[4-(4-acetyl-2-thienyl)phenyl]methylene}butyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-58-5 CAPLUS
CN Acetic acid, [4-[[3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-59-6 CAPLUS
CN Acetic acid, [4-[[3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-60-9 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-methoxy[1,1'-biphenyl])-4-y1)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-61-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3'-methoxy[1,1'-biphenyl])-4-y1)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 673480-62-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-y1)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-63-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-y1)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-64-3 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-65-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-66-5 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-(trifluoromethyl)(1,1'-biphenyl)-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-67-6 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[3'-(trifluoromethyl)(1,1'-biphenyl)-4-yl]-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-68-7 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-69-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-70-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-71-2 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)thio]phenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-72-3 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-73-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-phenoxyl[1,1'-biphenyl]-4-yl)-2-propenyl)oxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 673480-74-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(3'-phenoxyl)-4-yl}-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)




RN 673480-75-6 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-(1-methylethyl)-1,1'-biphenyl)-4-yl}-2-propenyl]thiophenoxy]- (9CI) (CA INDEX NAME)




RN 673480-76-7 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-(1-methylethyl)-1,1'-biphenyl)-4-yl}-2-propenyl]oxyphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673480-77-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl}oxyphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-78-9 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-propenyl}thiophenoxy]- (9CI) (CA INDEX NAME)




RN 673480-79-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}thiophenoxy]- (9CI) (CA INDEX NAME)




RN 673480-80-3 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl}oxyphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-81-4 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl}oxyphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673480-83-6 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl}thiophenoxy]- (9CI) (CA INDEX NAME)




RN 673480-85-8 CAPLUS
 CN Acetic acid, [4-[{2-[bis([1,1'-biphenyl]-4-yl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-87-0 CAPLUS
 CN Acetic acid, [4-[{2-[bis([1,1'-biphenyl]-4-yl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-89-2 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(5-methyl-2-furanyl)phenyl)methylene]butoxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-91-6 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(2-furanyl)phenyl)methylene]butoxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-94-9 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(5-methyl-2-furanyl)phenyl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673480-97-2 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(2-furanyl)phenyl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673480-99-4 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(5-chloro-2-thienyl)phenyl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-02-2 CAPLUS


CN Acetic acid, [4-{2-[bis(4-(5-chloro-2-thienyl)phenyl)methylene]butoxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-05-5 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(2-thienyl)phenyl)methylene]butoxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-08-8 CAPLUS
CN Acetic acid, [4-{2-[bis(4-(2-thienyl)phenyl)methylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-11-3 CAPLUS
CN Acetic acid, [4-{2-[bis(3'-(dimethylamino)carbonyl)[1,1'-biphenyl]-4-ylmethylene]butyl}thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-13-5 CAPLUS
CN Acetic acid, [4-{2-[bis(3'-(dimethylamino)carbonyl)[1,1'-biphenyl]-4-ylmethylene]butoxy}-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673481-16-8 CAPLUS
 CN Acetic acid, [4-[2-[bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-19-1 CAPLUS
 CN Acetic acid, [4-[2-[bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]methylene]butoxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-22-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-amino[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(3'-amino[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-32-8 CAPLUS
 CN Acetic acid, [4-[2-[bis[4-(2-pyridinyl)phenyl]methylene]butoxy]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-35-1 CAPLUS
 CN Acetic acid, [4-[2-[bis[4-(2-pyridinyl)phenyl]methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-24-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-amino[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-27-1 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-amino[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-29-3 CAPLUS



RN 673481-36-2 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-38-4 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy- (9CI) (CA INDEX NAME)




RN 673481-40-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(4'-methoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-42-0 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-methoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-44-2 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-47-5 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-50-0 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-methyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-53-3 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(4'-methyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-56-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-58-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-61-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(chloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-64-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-(chloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673481-67-9 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-(bis[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-70-4 CAPLUS
 CN Acetic acid, [4-[2-(bis[[1,1':4',1''-terphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-73-7 CAPLUS
 CN Acetic acid, [4-[2-(bis[4'-acetyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-76-0 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-acetyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-79-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(4'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-80-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(4'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-82-8 CAPLUS
 CN Acetic acid, [4-[2-[bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-84-0 CAPLUS
 CN Acetic acid, [4-[2-[bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673481-87-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-90-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-93-1 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-94-2 CAPLUS
 CN Acetic acid, [4-[2-[bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673481-97-5 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673481-99-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-00-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(4-methyl-2-furanyl)phenyl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 673482-02-5 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(4-methyl-2-furanyl)phenyl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-05-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(4-chloro-2-thienyl)phenyl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-07-0 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(4-chloro-2-thienyl)phenyl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673482-11-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(3-pyridinyl)phenyl)methylene]butoxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-13-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(3-pyridinyl)phenyl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 RN 673482-14-9 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-methoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-16-1 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-methoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-19-4 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-21-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-22-9 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-methyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-24-1 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(3'-methyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-27-4 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-29-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-31-0 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-chloro[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-34-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-chloro[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 673482-36-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(3'-1,1-dimethylallyl)-2-methoxybiphenyl]-4-yl]methoxy]butoxy-2-methoxybiphenyl - (9CI) (CA INDEX NAME)




RN 673482-39-8 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-acetyl[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methoxybiphenyl - (9CI) (CA INDEX NAME)




RN 673482-42-3 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-acetyl[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methoxybiphenyl - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-45-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butoxy]-2-methoxybiphenyl - (9CI) (CA INDEX NAME)




RN 673482-48-9 CAPLUS
 CN Acetic acid, [4-[2-[bis(3'-phenoxy[1,1'-biphenyl]-4-yl)methylene]butyl]thio]-2-methoxybiphenyl - (9CI) (CA INDEX NAME)



RN 673482-51-4 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(3'-1-methylallyl)[1,1'-biphenyl]-4-yl]methylene]butyl]thio]-2-methoxybiphenyl - (9CI) (CA INDEX NAME)



IT 673482-54-7P, [4-[(3,3-Bis(3'-isopropylbiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methoxybiphenyl acetic acid 673482-56-9P, [4-[(3,3-Bis(2',4'-difluorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methoxybiphenyl acetic acid 673482-58-1P, [4-[(3,3-Bis(2',4'-difluorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]-2-methoxybiphenyl acetic acid 673482-60-5P, [4-[(3,3-Bis(2',5'-dichlorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]-2-methoxybiphenyl acetic acid 673482-62-7P, [4-[(3,3-Bis(2',5'-dichlorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methoxybiphenyl acetic acid 673482-64-9P, [4-[(3,3-Bis(2'-chloro-4'-fluorobiphenyl)-4-yl)-2-ethylallyl]oxy]-2-methoxybiphenyl acetic acid 673482-66-1P, [4-[(3,3-Bis(2'-chloro-4'-fluorobiphenyl)-4-yl)-2-ethylallyl]sulfanyl]-2-methoxybiphenyl acetic acid 673482-71-8P, [4-[(3,3-Bis(biphenyl)-4-yl)-2-ethoxyallyl]oxy]-2-methoxybiphenyl acetic acid 673482-73-0P, [4-[(3,3-Bis(4-(5-methylfuran-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-75-2P, [4-[(3,3-Bis(4-furan-2-yl)phenyl)-2-ethoxyallyl]oxy]-2-methoxybiphenyl acetic acid 673482-77-4P, [4-[(3,3-Bis(4-(5-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-79-6P, [4-[(3,3-Bis(4-(5-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-81-0P, [4-[(3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-83-2P, [4-[(3,3-Bis(4-(5-chlorothiophen-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-85-4P, [4-[(3,3-Bis(4-(chlorophen-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-87-6P, [4-[(3,3-Bis(4-(thiophen-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-89-8P, [4-[(3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-91-2P, [4-[(3,3-Bis(4-(5-acetylthiophen-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-92-3P, [4-[(3,3-Bis(3'-methylsulfanyl)biphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673482-94-5P, [4-[(3,3-Bis(3'-methylsulfanyl)biphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-96-7P, [4-[(3,3-Bis(3'-aminobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673482-99-0P, [4-[(3,3-Bis(3'-aminobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-02-8P, [4-[(3,3-Bis(4-aminobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-03-9P, [4-[(3,3-Bis(4-aminobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-06-2P,

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 [4-[(3,3-Bis(4-(pyridin-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-09-5P, [4-[(3,3-Bis(4-(pyridin-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-10-8P, [4-[(3,3-Bis(4-(methanesulfonyl)biphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-13-1P, [4-[(3,3-Bis(4-(methanesulfonyl)biphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-16-4P, [4-[(3,3-Bis(3-(dimethylcarbamoyl)biphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-19-7P, [4-[(3,3-Bis(3-(dimethylcarbamoyl)biphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-22-2P, [4-[(3,3-Bis(4-(methoxybiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-23-3P, [4-[(3,3-Bis(4-(methoxybiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-26-6P, [4-[(3,3-Bis(4-(trifluoromethoxy)biphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-29-9P, [4-[(3,3-Bis(4-(trifluoromethoxy)biphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-32-4P, [4-[(3,3-Bis(4-(methylbiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-36-8P, [4-[(3,3-Bis(4-(methylbiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-39-1P, [4-[(3,3-Bis(4-(trifluoromethoxy)biphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-42-6P, [4-[(3,3-Bis(4-(trifluoromethoxy)biphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-45-7P, [4-[(3,3-Bis(4-(chlorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-48-0P, [4-[(3,3-Bis(4-(chlorobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-48-2P, [4-[(3,3-Bis(4-(tert-butylbiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-50-6P, [4-[(3,3-Bis(4-(acetylthiobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-55-1P, [4-[(3,3-Bis(4-(acetylthiobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-55-1P, [4-[(3,3-Bis(4-(4-acetylthiobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-57-3P, [4-[(3,3-Bis(4-(phenoxybiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-59-5P, [4-[(3,3-Bis(4-(phenoxybiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-61-9P, [4-[(3,3-Bis(4-(isopropylbiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-63-1P, [4-[(3,3-Bis(4-(isopropylbiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-65-3P, [4-[(3,3-Bis(3',4'-difluorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-67-5P, [4-[(3,3-Bis(3',4'-difluorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-67-5P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-69-7P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-72-2P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-74-4P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-77-7P, [4-[(3,3-Bis(3',5'-dichlorobiphenyl)-4-yl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-79-9P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-81-0P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-81-0P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-83-6P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-84-6P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-87-9P, [4-[(3,3-Bis(4-(4-methylfuran-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-91-5P, [4-[(3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)-2-ethoxyallyl)oxy]-2-methoxybiphenyl acetic acid 673483-93-7P, [4-[(3,3-Bis(4-(4-acetylthiophen-2-yl)phenyl)-2-ethoxyallyl)sulfanyl]-2-methoxybiphenyl acetic acid 673483-93-7P]

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



3-(*i*-yl)phenyl]-2-ethoxyallyl]oxy)-2-methylphenoxy)acetic acid
673483-95-9P, [4-[(3,3-Bis[4-(pyridin-3-yl)phenyl]-2-ethoxyallyl]sulfanyl)-2-methylphenoxy]acetic acid 673483-97-1P,
[4-[(3,3-Bis[3'-methoxybiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673483-99-3P, [4-[(3,3-Bis[3'-methoxybiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-01-0P,
[4-[(3,3-Bis[3'-methoxybiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-03-2P,
[4-[(3,3-Bis[3'-trifluoromethoxy)biphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-05-4P, [4-[(3,3-Bis[3'-methylbiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-07-6P, [4-[(3,3-Bis[3'-methylbiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-09-8P,
[4-[(3,3-Bis[3'-trifluoromethoxy)biphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-11-2P, [4-[(3,3-Bis[3'-trifluoromethoxy)biphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-13-4P, [4-[(3,3-Bis[3'-chlorobiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-15-6P,
[4-[(3,3-Bis[3'-chlorobiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-17-8P, [4-[(3,3-Bis[3'-tert-butylbiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-19-0P, [4-[(3,3-Bis[3'-acetyl)biphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-21-4P,
[4-[(3,3-Bis[3'-acetyl)biphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-23-6P, [4-[(3,3-Bis[3'-phenoxybiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-25-8P,
[4-[(3,3-Bis[3'-phenoxybiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-27-0P,
[4-[(3,3-Bis[3'-isopropylbiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-29-2P, [4-[(3,3-Bis[3'-isopropylbiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-31-6P, [4-[(3,3-Bis[2',4'-difluorobiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-33-8P,
[4-[(3,3-Bis[2',4'-difluorobiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-35-0P, [4-[(3,3-Bis[2',5'-dichlorobiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-37-2P, [4-[(3,3-Bis[2',5'-dichlorobiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-39-4P,
[4-[(3,3-Bis[2'-chloro-4'-fluorobiphenyl]-4-yl)-2-ethoxyallyl]oxy]-2-methylphenoxy)acetic acid 673484-41-6P, [4-[(3,3-Bis[2'-chloro-4'-fluorobiphenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-methylphenoxy)acetic acid 673484-43-0P, [4-[(3,3-Bis[2'-chlorophenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-45-2P, [4-[(3,3-Bis[2'-chlorophenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-47-4P,
[4-[(3,3-Bis[4-(5-methylfuran-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-49-6P, [4-[(3,3-Bis[4-(furan-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-51-0P, [4-[(3,3-Bis[4-(5-methylfuran-2-yl)phenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-53-2P, [4-[(3,3-Bis[4-(5-methylfuran-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-54-3P,
[4-[(3,3-Bis[4-(5-chlorothiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-56-5P, [4-[(3,3-Bis[4-(5-chlorothiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-58-7P, [4-[(3,3-Bis[4-(thiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-60-1P, [4-[(3,3-Bis[4-(thiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-62-3P, [4-[(3,3-Bis[4-(5-acetylthiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-63-4P,
[4-[(3,3-Bis[4-(5-acetylthiophen-2-yl)phenyl]-4-yl)-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-64-5P, [4-[(3,3-Bis[4-(5-

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

acetylthiophenyl]-2-ethoxyallyl]oxy]-2-chlorophenoxy)acetic acid 673484-65-6P, [4-[(3,3-Bis[4-(5-acetylthiophen-2-yl)phenyl]-2-ethoxyallyl)sulfanyl]-2-chlorophenoxy)acetic acid 673484-66-7P, [4-[(3,3-Bis[3'-methylsulfanylbiphenyl]-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-67-8P, [4-[(3,3-Bis[3'-methylsulfanylbiphenyl]-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-68-9P, [4-[(3,3-Bis[3'-aminobiphenyl]-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-70-1P, [4-[(3,3-Bis[3'-aminobiphenyl]-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-71-4P, [4-[(3,3-Bis[4-(aminobiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-72-5P, [4-[(3,3-Bis[4-(aminobiphenyl)-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-73-6P, [4-[(3,3-Bis[4-(pyridin-2-yl)phenyl]allyl)oxy]-2-chlorophenoxy)acetic acid 673484-74-7P, [4-[(3,3-Bis[4-(pyridin-2-yl)phenyl]allyl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-75-8P, [4-[(3,3-Bis[4-(methanesulfonyl)biphenyl]-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-76-9P, [4-[(3,3-Bis[4-(methanesulfonyl)biphenyl]-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-77-0P, [4-[(3,3-Bis[4-(methoxybiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-78-1P, [4-[(3,3-Bis[4-(methoxybiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-79-2P, [4-[(3,3-Bis[4-(trifluoromethoxy)biphenyl]-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-80-5P, [4-[(3,3-Bis[4-(trifluoromethoxy)biphenyl]-4-yl)allyl]oxy]-2-chlorophenoxy)acetic acid 673484-81-6P, [4-[(3,3-Bis[4-(4'-methylbiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-82-7P, [4-[(3,3-Bis[4-(4'-methylbiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-83-8P, [4-[(3,3-Bis[4-(trifluoromethoxy)biphenyl]-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-84-9P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-85-0P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-86-1P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-87-2P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-88-3P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-89-4P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-90-5P, [4-[(3,3-Bis[4-(chlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-91-6P, [4-[(3,3-Bis[4-(isopropylbiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-92-7P, [4-[(3,3-Bis[4-(isopropylbiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-93-8P, [4-[(3,3-Bis[4-(3',4'-difluorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-94-1P, [4-[(3,3-Bis[4-(3',4'-difluorobiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-95-2P, [4-[(3,3-Bis[4-(5',5"-dichlorobiphenyl)-4-yl)allyl]sulfanyl]-2-chlorophenoxy)acetic acid 673484-97-4P, [4-[(3,3-Bis[4-(5',5"-dichlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-98-5P, [4-[(3,3-Bis[4-(5',5"-dichlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-99-6P, [4-[(3,3-Bis[4-(5',5"-dichlorobiphenyl)-4-yl)allyl]oxy)-2-chlorophenoxy)acetic acid 673484-99-7P, RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (PPAR agonist; prepn. of di(hetero)arylvinylic carboxylic acids as PPAR agonists for treatment of diabetes and related conditions)



RN 673482-54-7 CAPLUS
CN Acetic acid, [4-[(2-[bis(3',5'-dichlorobiphenyl)-4-yl)methylene]butyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 673482-60-5 CAPLUS
CN Acetic acid, [4-[(2-[bis(2',5'-dichlorobiphenyl)-4-yl)methylene]butyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)






RN 673482-66-1 CAPLUS
CN Acetic acid, [4-[(2-[bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methylene]butylthio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-71-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis([1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-73-0 CAPLUS
CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(2-furanyl)phenyl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-81-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-(5-chloro-2-thienyl)phenyl)-2-ethoxy-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-83-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis(4-(5-chloro-2-thienyl)phenyl)-2-ethoxy-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673482-75-2 CAPLUS
CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(2-furanyl)phenyl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-77-4 CAPLUS
CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(5-methyl-2-furanyl)phenyl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-79-6 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(2-thienyl)phenyl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673482-85-4 CAPLUS
CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(2-thienyl)phenyl)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-87-6 CAPLUS
CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4-(2-thienyl)phenyl)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673482-89-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(4-(5-acetyl-2-thienyl)phenyl)-2-ethoxy-2-propenyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-91-2 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-(5-acetyl-2-thienyl)phenyl)-2-ethoxy-2-propenyl)oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-92-3 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673482-94-5 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl)oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-96-7 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis[3'-(amino)[1,1'-biphenyl]-4-yl]-2-propenyl)oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673482-99-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-02-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-03-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl)oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-06-2 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl)oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-09-5 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl)thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-10-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-13-1 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-16-4 CAPLUS
 CN Acetic acid, [4-[3,3-bis[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-19-7 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[3'-(dimethylamino)carbonyl][1,1'-biphenyl]-4-yl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-22-2 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 673483-23-3 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis(4'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-26-6 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-29-9 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-32-4 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis(4'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-36-8 CAPLUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis(4'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-39-1 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4'-trifluoromethyl)[1,1'-biphenyl]-4-y1)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-42-6 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4'-trifluoromethyl)[1,1'-biphenyl]-4-y1)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-43-7 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-chlorophenyl)-4-y1)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-46-0 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-chlorophenyl)-4-y1)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-48-2 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-dimethylpropyl)-1,1'-biphenyl)-4-y1)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-50-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis((1,1':4',1''-terphenyl)-4-y1)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-52-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-acetyl[1,1'-biphenyl]-4-y1)-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-55-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-acetyl[1,1'-biphenyl]-4-y1)-2-ethoxy-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-57-3 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-y1)-2-propenyl]oxy)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-59-5 CAPLUS
 CN Acetic acid, [4-[(2-ethoxy-3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-61-9 CAPLUS

L4 ANSWER 3 OF 3 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenylthio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-63-1 CAPIUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-yl]-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-65-3 CAPIUS
 CN Acetic acid, [4-[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673483-67-5 CAPIUS
 CN Acetic acid, [4-[3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenylthio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-70-0 CAPIUS
 CN Acetic acid, [4-[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenylthio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-72-2 CAPIUS

L4 ANSWER 3 OF 3 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-74-4 CAPIUS
 CN Acetic acid, [4-[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-77-7 CAPIUS
 CN Acetic acid, [4-[3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenylthio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPIUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673483-79-9 CAPIUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-81-3 CAPIUS
 CN Acetic acid, [4-[2-ethoxy-3,3-bis[4-(4-methyl-2-furanyl)phenyl]-2-propenylthio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673483-84-6 CAPLUS
 CN Acetic acid, [4-[[3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-87-9 CAPLUS
 CN Acetic acid, [4-[[3,3-bis[4-(4-chloro-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-89-1 CAPLUS
 CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-91-5 CAPLUS
 CN Acetic acid, [4-[[3,3-bis[4-(4-acetyl-2-thienyl)phenyl]-2-ethoxy-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-93-7 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-95-9 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-97-1 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673483-99-3 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis(3'-methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673484-01-0 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-03-2 CAPLUS
 CN Acetic acid, [4-[[2-ethoxy-3,3-bis(3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)




RN 673484-05-4 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-07-6 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-methyl[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-09-8 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-11-2 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-2-propenyl}oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-13-4 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-15-6 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(3'-chloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-17-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[3'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]-2-ethoxy-2-propenyl}oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-19-0 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-21-4 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-acetyl[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl}oxy]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-23-6 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl}thio]-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-25-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-phenoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-27-0 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-29-2 CAPLUS
 CN Acetic acid, [4-[{2-ethoxy-3,3-bis(3'-(1-methylethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]oxy}-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-31-6 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-33-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',4'-difluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-35-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-37-2 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2',5'-dichloro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-39-4 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]oxy}-2-methylphenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673484-41-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(2'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-ethoxy-2-propenyl]thio}-2-methylphenoxy] - (9CI) (CA INDEX NAME)




RN 673484-43-0 CAPLUS
 CN Acetic acid, [4-[{3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl]thio}-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-45-2 CAPLUS
 CN Acetic acid, [4-[{3,3-bis([1,1'-biphenyl]-4-yl)-2-propenyl]oxy}-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-47-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-49-6 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(2-furanyl)phenyl]-2-propenyl]oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-51-0 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(5-methyl-2-furanyl)phenyl]-2-propenyl]thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 673484-53-2 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(2-furanyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-54-3 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-56-5 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Acetic acid, [4-[(3,3-bis[4-(5-chloro-2-thienyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-58-7 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(2-thienyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-60-1 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(2-thienyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)



RN 673484-62-3 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl)thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-63-4 CAPLUS
CN Acetic acid, [4-[(3,3-bis[4-(5-acetyl-2-thienyl)phenyl]-2-propenyl)oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-64-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[2-[bis(4-(5-acetyl-2-thienyl)phenyl)methylene]butoxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-65-6 CAPLUS
 CN Acetic acid, [4-[2-[bis(4-(5-acetyl-2-thienyl)phenyl)methylene]butyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-66-7 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[{3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-71-4 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-72-5 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(4'-amino[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-67-8 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[3'-(methylthio)[1,1'-biphenyl]-4-yl]-2-propenyl}oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-68-9 CAPLUS
 CN Acetic acid, [4-[{3,3-bis(3'-amino[1,1'-biphenyl]-4-yl)-2-propenyl}oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-69-0 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-73-6 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl}oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-74-7 CAPLUS
 CN Acetic acid, [4-[{3,3-bis[4-(2-pyridinyl)phenyl]-2-propenyl}thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-75-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Acetic acid, [4-[{3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl]thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-76-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-propenyl}oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-77-0 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]oxy}-2-chlorophenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-78-1 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(methoxy[1,1'-biphenyl]-4-yl)-2-propenyl]thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-79-2 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl]thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-80-5 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Acetic acid, [4-[{3,3-bis[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl)-2-propenyl}oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-81-6 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(methyl[1,1'-biphenyl]-4-yl)-2-propenyl]thio}-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-82-7 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl]thio)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-83-8 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)-2-propenyl}oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-84-9 CAPLUS
CN Acetic acid, [4-[{3,3-bis[4'-(chloro[1,1'-biphenyl]-4-yl)-2-propenyl}oxy)-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-85-0 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(4'-chlorophenoxy)-2-propenyl)thio]-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-86-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-y1)-2-propenyl]oxy]-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-87-2 CAPLUS
 CN Acetic acid, [4-[(3,3-bis([1,1':4',1'''-terphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-88-3 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-acetyl[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-89-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-y1)-2-propenyl]oxy)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-90-7 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(4'-phenoxy[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-91-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-92-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[4'-(1-methylethyl)[1,1'-biphenyl]-4-y1)-2-propenyl]oxy)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673484-93-0 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-94-1 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3',4'-difluoro[1,1'-biphenyl]-4-y1)-2-propenyl]thio)-2-chlorophenoxy] - (9CI) (CA INDEX NAME)




RN 673484-96-3 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 CN Acetic acid, [4-[(3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-97-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3',5'-dichloro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




RN 673484-98-5 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]oxy]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 673484-99-6 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(3'-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)-2-propenyl]thio]-2-chlorophenoxy]- (9CI) (CA INDEX NAME)




IT 673479-08-6P, [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid methyl ester 673479-09-9P,
 [4-[(3,3-Bis(4-bromophenyl)allyl)sulfanyl]-2-methylphenoxy]acetic acid 673479-20-4P, [4-[(3,3-Bis(4-pyridin-3-yl)phenyl)allyl)sulfanyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Intermediate preparation of di(hetero)arylvinylic carboxylic acids as PPAR δ agonists for treatment of diabetes and related conditions)
 RN 673479-08-8 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 673479-09-9 CAPLUS
 CN Acetic acid, [4-[(3,3-bis(4-bromophenyl)-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 673479-20-4 CAPLUS
 CN Acetic acid, [4-[(3,3-bis[4-(3-pyridinyl)phenyl]-2-propenyl)thio]-2-(trifluoromethylphenoxy)-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 1-3

DOCUMENT NUMBER: 140:374984

TITLE: Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIIXKD
DOCUMENT TYPE: Patent
LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	A1	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:		DK 2002-1631	A 20021028	
		DK 2003-793	A 20030526	
		US 2002-423467P	P 20021104	
		WO 2003-DK722	W 20031027	

OTHER SOURCE(S): MARPAT 140:374984

GI



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mists, of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR δ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobiphenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

ACCESSION NUMBER: 2004:370891 CAPLUS

DOCUMENT NUMBER: 140:391127

TITLE: Preparation of biphenylallylsulfanylphenoxycetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIIXKD

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	A1	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:		DK 2002-1629	A 20021028	
		US 2002-423644P	P 20021104	
		WO 2003-DK723	W 20031027	

OTHER SOURCE(S): MARPAT 140:391127

GI



AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy]acetic acid (preparation given), Phb(OH)2, KF, Pd2(dba)3, and Pd[P(tBu)3]2 were stirred in THF to give [4-(3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl)phenoxy]acetic acid.

ACCESSION NUMBER: 2004:220310 CAPLUS

DOCUMENT NUMBER: 140:270625

TITLE: Preparation of [[(bis(biphenyl)allyl)allyl]oxy]phenoxy]acetic acids and analogs as PPAR δ agonists for treatment of diabetes and related conditions

INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIIXKD

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022533	A1	20040318	WO 2003-DK578	20030904
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
CA 2499380	AA	20040318	CA 2003-2499380	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793608	20030904
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:		DK 2002-1301	A 20020905	
		DK 2003-784	A 20030523	
		US 2002-409814P	P 20020911	
		WO 2003-DK578	W 20030904	

OTHER SOURCE(S): MARPAT 140:270625

GI

10/69376 (b) 8/13/05

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:12:32 ON 13 AUG 2005

FILE 'REGISTRY' ENTERED AT 17:12:41 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
Structure search iteration limits have been increased. See HELP SLIMITS
for details.
```

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> Uploading C:\Program Files\Stnexp\Queries\10693161\10693161b.str



```

chain nodes :
1 2 3 4 5 7 8 9 11 12 15 16
chain bonds :
1-3 2-3 3-4 4-5 5-7 7-8 8-9 9-11 11-12 12-15 12-16
exact/norm bonds :
5-7 7-8 8-9 9-11 12-15 12-16
exact bonds :
1-3 2-3 3-4 4-5 11-12

```

G1:O,S

```

Match level :
1:Atom 2:Atom 3:CLASS 4:CLASS 5:CLASS 7:CLASS 8:Atom 9:CLASS 11:CLASS
12:CLASS 15:CLASS 16:CLASS

```

L1 STRUCTURE UPLOADED

```

=> d
L1 HAS NO ANSWERS
L1 STR

```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s L1
SAMPLE SEARCH INITIATED 17:13:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53506 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 632

L2 2 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 17:13:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 93.6% PROCESSED 1000000 ITERATIONS 505 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.15

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 505

L3 505 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.76 161.97

FILE 'CAPLUS' ENTERED AT 17:13:39 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L3
L4 3 L3



=> d ibib abs 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370892 CAPLUS
 DOCUMENT NUMBER: 140:374984
 TITLE: Preparation of [(diarylethyl)sulfanyl]phenoxy)acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
 INVENTOR(S): Jeppeesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NJ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MR, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:		DK 2002-1631	A 20021028	
		DK 2003-793	A 20030526	
		US 2002-423467P	P 20021104	
		WO 2003-DK722	W 20031027	

OTHER SOURCE(S): MARPAT 140:374984
 GI

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I (wherein X1 and X2 = independently (un)substituted heteroaryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or

S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of

stereoisomers, or polymers thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR δ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate


in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid

Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370891 CAPLUS
 DOCUMENT NUMBER: 140:391127
 TITLE: Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases
 INVENTOR(S): Jeppeesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NJ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	AA	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MR, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:		DK 2002-1629	A 20021028	
		US 2002-423644P	P 20021104	
		WO 2003-DK723	W 20031027	

OTHER SOURCE(S): MARPAT 140:391127
 GI



L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PHB(OH)2, KF, Pd2(dba)3, and Pd(P(tBu)3)2 were stirred in THF to give [4-(3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl)phenoxy]acetic acid.

AB Title compds. I (I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.) were prepared for treatment of PPAR mediated disease (no data). Thus, [4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy]acetic acid (preparation given),

DOCUMENT NUMBER: 140:270625

TITLE: Preparation of

$\{[(\text{bis}(\text{biphenyl})\text{allyl})\text{oxy}]\text{phenoxy}\}\text{ace}$
 tic acids and analogs as PPAR δ agonists for
 treatment of diabetes and related conditions

INVENTOR(S): Jeppeesen, Lone; Mogensen, John Patrick; Pettersson,
 Ingrid; Sauerberg, Per
 Novo Nordisk A/S, Den.

PATENT ASSIGNEE(S): PCT Int. Appl., 78 pp.

SOURCE: CODEN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200402533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA	ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CF, CO, CI, GA, GN, GQ, GU, ML, MR, NE, SN, TD, TG	ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BY, BJ, CF, CO, CI, GA, GN, GQ, GU, ML, MR, NE, SN, TD, TG	CA 2499380	AA 20040318 CA 2003-2499380 20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793608	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	DK 2002-1301	A 20020905	DK 2003-784	A 20030523
PRIORITY APPLN. INFO.:			US 2002-409814P	P 20020911
OTHER SOURCE(S):	MARPAT 140:270625		WO 2003-DK578	W 20030904
G1				



AB Title vinyl carboxylic acid derivs. I (wherein X1 and X3 = independently (un)substituted (hetero)aryl; X2 and X4 = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y1 and Y2 = independently

O or S; Z = $(\text{CH}_2)_n$; n = 1-3; R1 = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkyne, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio); R2 = H, (cyclo)alkyl, alkenyl, alkyne, or aryl; or pharmaceutically acceptable salts,

solvates, tautomers, stereoisomers, or polymorphs thereof) were prepared as peroxisome

proliferator-activated receptor δ (PPAR δ) agonists (no data). For example, 4,4'-dibromobenzophenone was coupled with tri-Et

phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DBAL-H in THF (76%),


followed by ADDP-catalyzed condensation with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded (4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy)acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF,

Pd2(dba)3, and Pd(P(t-Bu)3)2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR δ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161c.str



chain nodes :

1 2 3 5 6 7 9 10 13 14

ring nodes :

15 16 17 18 19 20 21 22 23 24 25 26

chain bonds :

1-2 1-15 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14

ring bonds :

15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

3-5 5-6 6-7 7-9 10-13 10-14

exact bonds :

1-2 1-15 1-21 2-3 9-10
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

G1:O,S

Match level :

1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS
14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom

L5 STRUCTURE UPLOADED

=> fil reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 9.75 171.72

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -2.19 -2.19

FILE 'REGISTRY' ENTERED AT 17:15:54 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

\Rightarrow

Uploading C:\Program Files\Stnexp\Queries\10693161\10693161c.str



chain nodes :

1 2 3 5 6 7 9 10 13 14

ring nodes :

15 16 17 18 19 20 21 22 23 24 25 26

chain bonds

1-2 1-15 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14

ring bonds :

15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

exact/norm bonds :

3-5 5-6 6-7 7-9 10-13 10-14

exact bonds :
1-2 1-15 1-21 2-3 9-10
normalized bonds :
15-16 15-20 16-17 17-18 18-19 19-20 21-22 21-26 22-23 23-24 24-25 25-26

G1:O,S

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS
14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom

L6 STRUCTURE UPLOADED

=> d
L6 HAS NO ANSWERS
L6 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s L6
SAMPLE SEARCH INITIATED 17:16:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 158 TO ITERATE

100.0% PROCESSED 158 ITERATIONS 25 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2406 TO 3914
PROJECTED ANSWERS: 200 TO 800

L7 25 SEA SSS SAM L6

=> s L6 full
FULL SEARCH INITIATED 17:16:31 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3372 TO ITERATE

100.0% PROCESSED 3372 ITERATIONS 505 ANSWERS
SEARCH TIME: 00.00.01

L8 505 SEA SSS FUL L6

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 161.33 333.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -2.19

FILE 'CAPPLUS' ENTERED AT 17:16:37 ON 13 AUG 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s L8
L9          3 L8
=> d ibib abs 1-3
```

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:370892 CAPLUS

DOCUMENT NUMBER: 140-374984

TITLE: Preparation of [(diarylethyl)sulfanyl]phenoxy)acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Plihara, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 124 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1621 A 20021028				
	DK 2003-793	A 20030526		
	US 2002-423467P	P 20021104		
	WO 2003-DK722	W 20031027		

OTHER SOURCE(S): MARPAT 140:374984
GI

L9 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or

S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of

stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR δ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate

in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid

Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370891 CAPLUS

DOCUMENT NUMBER: 140-391127

TITLE: Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Plihara, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	AA	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1629 A 20021028				
	US 2002-423644P	P 20021104		
	WO 2003-DK723	W 20031027		

OTHER SOURCE(S): MARPAT 140:391127
GI



L9 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PhB(OH)2, KF, Pd2(dba)3, and Pd(P(tBu)3)2 were stirred in THF to give [4-(3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy)acetic acid.



AB Title compds. I [wherein X1, X2, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-(3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl)-2-methylphenoxy)acetic acid (preparation given),

$\{[(\text{biphenyl-}4\text{-yl})\text{allyl}] \text{oxy}\}$ phenoxy)acetic acids and analogs as PPAR δ agonists for treatment of diabetes and related conditions
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200402533	A1	20040318	WO 2003-DK578	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NI, NO, NQ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IB, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499380	AA	20040318	CA 2003-2499380	20030904
US 2004143006	A1	20040722	US 2003-654699	20030904
EP 1537076	A1	20050608	EP 2003-793608	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1301	A	20020905		
	DK 2003-784	A 20030523		
	US 2002-409814P	P 20020911		
	WO 2003-DK578	W 20030904		

OTHER SOURCE(S): MARPAT 140:270625
GI



AB Title vinyl carboxylic acid derivs. I (wherein X₁ and X₃ = independently (un)substituted (hetero)aryl; X₂ and X₄ = independently (un)substituted (hetero)arylene; Ar = (un)substituted arylene; Y₁ and Y₂ = independently

O or S; Z = (CH₂)_n; n = 1-3; R₁ = H, halo, or (un)substituted (cyclo)alkyl, alkenyl, alkyanyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, arylthio; R₂ = H, (cyclo)alkyl, alkenyl, alkyanyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator-activated receptor δ (PPAR δ) agonists (no data). For example, 4,4'-dibromobenzenophenone was coupled with tri-Et phosphonoacetate in the presence of NaH in toluene to give Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction using DIBAL-H in THF (76%), followed by ADDP-catalyzed condensation with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in THF (88%) afforded [4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy]acetic acid Me ester. Saponification (93%) and substitution with phenylboronic acid using KF, Pd2(dba)3, and Pd(P(t-Bu)3)2 in THF (53%) provided II. Also disclosed is the use of I and their pharmaceutical compns. for the treatment of PPAR δ -mediated conditions, such as diabetes, impaired glucose tolerance, insulin resistance, or obesity (no data).
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> fil reg
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                                ENTRY          SESSION
FULL ESTIMATED COST          9.75           342.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE      TOTAL
                                                ENTRY          SESSION
CA SUBSCRIBER PRICE          -2.19           -4.38
```

FILE 'REGISTRY' ENTERED AT 17:19:11 ON 13 AUG 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7
 DICTIONARY FILE UPDATES: 12 AUG 2005 HIGHEST RN 860111-75-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*****
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\10693161\10693161d.str
```



```

chain nodes :
1 2 3 5 6 7 9 10 13 14 15 16
chain bonds :
1-2 1-15 1-16 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14
exact/norm bonds :
1-15 1-16 3-5 5-6 6-7 7-9 10-13 10-14
exact bonds :
1-2 2-3 9-10

```

G1:O, S

```

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS
14:CLASS 15:Atom 16:Atom

```

=> d
L10 HAS NO ANSWERS
L10 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
Structure attributes must be viewed using STN Express query preparation.

=> s L10
SAMPLE SEARCH INITIATED 17:19:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53506 TO ITERATE

3.7% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L11 0 SEA SSS SAM L10

=> s L10 full
FULL SEARCH INITIATED 17:19:33 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 93.6% PROCESSED 1000000 ITERATIONS 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.14

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 8

L12 8 SEA SSS FUL L10

=> fil caplus			
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION	
FULL ESTIMATED COST	161.33	504.13	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION	
CA SUBSCRIBER PRICE	0.00	-4.38	

FILE 'CAPLUS' ENTERED AT 17:19:53 ON 13 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2005 VOL 143 ISS 8
FILE LAST UPDATED: 12 Aug 2005 (20050812/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L12
L13 2 L12



=> d ibib abs 1-2

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370892 CAPLUS
 DOCUMENT NUMBER: 140:374984
 TITLE: Preparation of [(diaryllallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
 INVENTOR(S): Jeppesen, Lone; Mogenesen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1631			A 20021028	
		DK 2003-793	A 20030526	
		US 2002-423467P	P 20021104	
		WO 2003-DK722	W 20031027	

OTHER SOURCE(S): MARPAT 140:374984
 GI

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Title compds. I (wherein X1 and X2 = independently (un)substituted heteroaryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenylnyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR δ , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid Me ester in the presence of ADPP and tributylphosphine in THF gave II (88%).

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:370891 CAPLUS
 DOCUMENT NUMBER: 140:391127
 TITLE: Preparation of biphenylallylsulfanylphenoxycetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases
 INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
 PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIIXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	AA	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1629			A 20021028	
		US 2002-423644P	P 20021104	
		WO 2003-DK723	W 20031027	

OTHER SOURCE(S): MARPAT 140:391127
 GI



L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PhB(OH)2, KF, Pd2(dba)3, and Pd(P(tBu)3)2 were stirred in THF to give [4-(3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl)phenoxy]acetic acid.

AB Title compds. (I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.), were prepared for treatment of PPAR mediated disease (no data). Thus, (4-(3,3-bis(4-bromophenyl)allylsulfanyl)-2-methylphenoxy)acetic acid (preparation given).

```
=> d ibib abs 1-2 fhitstr
```

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:370892 CAPLUS
DOCUMENT NUMBER: 140:374984


TITLE: Preparation of [(diarylallyl)sulfanylphenoxyl]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIIXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1631	A	20021028		
DK 2003-793	A	20030526		
US 2002-423467P	P	20021104		
WO 2003-DK722	W	20031027		

OTHER SOURCE(S): MARPAT 140:374984
GI

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Title compds. I (wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenylnyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof) were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPAR α , such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesterolemia (no data).

For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercaptop-2-methylphenoxy)acetic acid

Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

IT 685139-48-4P, [4-[(3,3-Bis(3-methylthiophen-2-yl)allyl)sulfanyl]-2-trifluoromethylphenoxy]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic uses); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR activator; preparation of [(diarylallyl)sulfanyl]phenoxylacetates as PPAR activators for treatment of diabetes and related conditions)

RN 685139-48-4 CAPLUS

CN Acetic acid, [4-[(3,3-bis(3-methyl-2-thienyl)-2-propenyl)thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370891 CAPLUS

DOCUMENT NUMBER: 140:391127

TITLE: Preparation of biphenylallylsulfanylphenoxylacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases

INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 69 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TU, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	AA	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: DK 2002-1629	A	20021028		
		US 2002-423644P	P	20021104
		WO 2003-DK723	W	20031027


OTHER SOURCE(S): MARPAT 140:391127

GI



AB Title compds. I (X1, X2 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, Y2 = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.) were prepared for treatment of PPAR mediated disease (no data). Thus, (4-[3,3-bis(4-bromophenyl)allylsulfanyl]-2-methylphenoxy)acetic acid (preparation given).

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
 PhB(OH)2, KF, Pd2(dba)3, and Pd(P(tBu)3)2 were stirred in THF to give
 {4-[3-(4-biphenyl-4-yl)-3-(4-bromophenyl)allylsulfanyl]phenoxy}acetic acid.
 IT 686774-28-7
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of biphenylallylsulfanylphenoxyacetates and related
 compds. for treating peroxisome proliferator activated receptor (PPAR) mediated
 diseases)
 RN 686774-28-7 CAPLUS
 CN Acetic acid,
 [2-methyl-4-{[3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio}phenoxy]- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.08	520.21
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.92	-7.30

STN INTERNATIONAL LOGOFF AT 17:20:53 ON 13 AUG 2005